This inventor holds 3 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Lupin, Inc., Les Laboratoires Servier. Active years: 2009-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Pune, IN (2009 - 2012)
- Maharashtra, IN (2019)
Company Filing History:
Years Active: 2009-2019
Title: Rajinder Singh Siyan: Innovator in Pharmaceutical Processes
Introduction
Rajinder Singh Siyan is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of processes for synthesizing important compounds. With a total of 3 patents to his name, Siyan's work has the potential to impact the industry positively.
Latest Patents
One of his latest patents is a process for the preparation of cysteamine bitartrate. This invention involves reacting cysteamine or its salt with tartaric acid. The patent also describes two crystalline forms of cysteamine bitartrate, L1 and L2, each characterized by specific diffraction peaks in their X-ray diffraction patterns. Another significant patent is for an improved process for the synthesis of duloxetine hydrochloride, which boasts a chiral purity greater than 99.9%. This advancement is crucial for ensuring the efficacy and safety of the medication.
Career Highlights
Throughout his career, Rajinder Singh Siyan has worked with reputable companies such as Lupin, Inc. and Les Laboratoires Servier. His experience in these organizations has allowed him to refine his skills and contribute to innovative pharmaceutical solutions.
Collaborations
Siyan has collaborated with notable professionals in the field, including Girij Pal Singh and Debashish Datta. These partnerships have likely enhanced his research and development efforts.
Conclusion
Rajinder Singh Siyan's contributions to pharmaceutical processes through his patents demonstrate his commitment to innovation in the industry. His work continues to pave the way for advancements in drug synthesis and formulation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

